Search

Your search keyword '"Möller, B."' showing total 921 results

Search Constraints

Start Over You searched for: Author "Möller, B." Remove constraint Author: "Möller, B."
921 results on '"Möller, B."'

Search Results

101. Towards Multi-Level Security for NATO Collective Mission Training – a White Paper

102. Toward a Data Logging Data Interchange Format: Use Cases and Requirements

103. A novel screening strategy for preclinical rheumatoid arthritis (RA) in first degree relatives of patients with RA

104. Biologics in rheumatoid arthritis - recommendations for Swiss practice

106. AB0251 Female Reproductive Factors and the Development of Anti-Citrullinated Protein Antibodies in Women at Risk of Rheumatoid Arthritis

109. Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study

110. Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent?

111. Cyclophilin 40 is required for microRNA activity in Arabidopsis

113. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

114. Postersitzung 14: Urolithiasis — Metaphylaxe und Infektprophylaxe

115. The Munich Project CIP

122. THU0238 Risk Factors for the Development of Anti-Citrullinated Protein Antibodies in Individuals Genetically at Risk for RA

123. P747 ASSOCIATION OF A GENETIC VARIANT OF THE MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN (MAVS) WITH INTERFERON RESPONSE IN CHRONIC HEPATITIS C VIRUS INFECTION

125. Patient-related predictors of treatment satisfaction of patients with fibromyalgia syndrome: Results of a cross-sectional survey

126. Analysis of Object Interactions in Dynamic Scenes

127. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction

128. Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis

130. Leukocytes decline > 2500/µl during Peginterferon Alfa-2B (PEG-2B)/Ribavirin (RBV) treatment predicts favorable SVR rates in difficult-to-treat patients with HCV Genotype 1 (G1) infection in real-life

132. Thyroid dysfunction induced by peginterferon alfa-2b (Peg-2b)/Ribavirin (Rbv) is associated with higher SVR rates in patients with HCV Genotype 1 (G1) infection due to improved early virologic response at week 4 and week 12

139. 797 HIGH PREVALENCE OF CHRONIC HEPATITIS C IN 8009 PATIENTS WITH MIGRATION BACKGROUND LIVING IN GERMANY

140. 9 ASSOCIATION OF A GENETIC VARIANT OF THE TOLL-LIKE RECEPTOR 9 (TLR9) WITH SPONTANEOUS VIRAL CLEARANCE AND WITH INTERFERON RESPONSE IN CHRONIC HEPATITIS C VIRUS INFECTION

141. 912 LEUKOCYTE DECLINE PREDICTS SUSTAINED VIROLOGIC RESPONSE IN PATIENTS UNDERGOING PEGINTERFERON alfa-2b/RIBAVIRIN TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION

143. Thyroid dysfunction induced by Peginterferon alfa-2B (PEG-2B)/Ribavirin (RBV) is a favorable predictor of SVR in patients with HCV genotype 1 (G1), but not HCV genotype 2/3 (G2/3) infection

144. Age- and gender-related differences in SVR and relapse following treatment of HCV genotype 3 (G3) infection with Peginterferon alfa-2b (peg2b)/Ribavirin (RBV) in real-life

145. Association of genetic variants in innate immunity genes with spontaneous viral clearance and with interferon response in chronic hepatitis C virus infection

146. Hemoglobin decline above 2g/dl during Peginterferon alfa-2b (PEG-2B)/Ribavirin (RBV) treatment predicts favorable SVR in patients with HCV genotype 1 and HCV genotype 2/3 infection without erythropoietin use

147. Sicherheitsbeurteilung von Tragwerken mit Fuzzy-Modellen

Catalog

Books, media, physical & digital resources